Atara Biotherapeutics, Inc. (ATRA) on Q2 2021 Results - Earnings Call Transcript
Operator: Good afternoon, everyone, thank you for standing by. And welcome to the Atara Biotherapeutics Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. Please be advised that today's call is being recorded. I now would like to hand the call over to Eric Hyllengren, Vice President of Investor Relations and Finance at Atara Biotherapeutics. Please go ahead, sir.
Eric Hyllengren: Thank you, operator. Good afternoon, everyone, and welcome to Atara's second quarter 2021 results conference call. Earlier today, we issued a press release announcing our second quarter financial results and operational progress. This press release and an updated investor presentation are available in the Investors and Media section at atarabio.com. On today's call, members from the Atara executive team will provide an update on our financial results and operational progress and also review our upcoming key milestones and objectives. Joining me on today's call are Dr. Pascal Touchon, President and Chief Executive Officer; Dr. Jakob Dupont, Executive Vice President and Global Head of Research and Development; Utpal Koppikar Chief Financial Officer; Joe Newell, Chief Operations Officer; Dr. Jose Vidal, Head of GMP Quality and Process Sciences; Dr. AJ Joshi, Chief Medical Officer; and Dr. Kristin Yarema, Chief Commercial Officer. We will begin with prepared comments from Pascal and Jakob then open up the call for your questions. We would like to remind listeners that during the call, the Company's management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the Company's business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press release and the Company's SEC filings. These statements are made as of today's date and the Company undertakes no obligation to update these statements. Now, I'd like to turn the call over to Pascal. Pascal?
Pascal Touchon: Thank you, Eric, and thank you, all for joining us this afternoon. We have completed a strong first half of 2021, and are making good progress on all three of our strategic priorities, tab-cel, ATA188 in multiple sclerosis, and our next-generation allogeneic CAR T programs. Supported by a breakthrough therapy designation, we have been having regular dialogues since January with the FDA. We recently conducted positive meetings with the regulatory team at the FDA and gained alignment, clarity and actionable next steps in order to submit the tab-cel BLA. First, we gained alignment with the FDA on the key methodologies for evaluating comparability between tab-cel clinical and commercial products. In addition, the FDA asked for and we will provide to them data on substantially all tab-cel lots made to date by Atara. We believe this should clear the way for the FDA to make a determination at an upcoming Type B CMC meeting regarding our expanded data package supporting comparability between the product used in the pivotal clinical study and the intended commercial product. Next, the FDA decided it cannot make a determination of comparability between the non-pivotal product and the pivotal clinical study product. And clinical data from the historical non-pivotal study will not be pulled with the pivotal ALLELE study data, rather we intend to present these data in parallel as part of the BLA submission. Importantly, at this time, the FDA has made no new request of Atara to conduct additional clinical studies, develop new assays or conduct new manufacturing of lots. We are confident that we will have a robust data package to demonstrate comparability to the FDA between pivotal and commercial process versions of tab-cel and we are encouraged by the ongoing interactions as we work towards finalizing of CMC Module 3 post the FDA submission. Turning to the pivotal ALLELE study. We have recently successfully completed the analysis of the Q2 that occurred previously requested by the FDA. Top line data shows strong objective response rate in line with prior results and a consistent safety profile with no new safety signals. In addition, we now have new robust durability data as well. These data from a pivotal study are impressive for such an ultra-rare and high-unmet need conditions like relapsed refractory PTLD where patients have no treatment options. The latest that occurred will be still discussed with the FDA for the Type B clinical meeting and is what we plan to use as the basis of both the BLA and the MAA submissions. As a reminder, we continue to plan to present this Phase 3 ALLELE data at an appropriate congress in Q4 2021. Looking ahead, we know our clarity on the required next steps for resolution and submission of the BLA for tab-cel. Although these have taken some time as Atara is a trailblazer for allogeneic cell therapy as a whole and is paving the way for the first-ever allogeneic of the shelf T cell therapy to which figures we're finding, we now expect to complete the BLA submission for tab-cel in Q1 2022. Our investment in US commercial readiness activities have been shifted to this new timing, gating of spending versus what was previously anticipated, as we now plan for tab-cel approval and US launch in the second half of 2022. As we continue to prepare for commercial launch, I'm very pleased to announce that cell therapy and oncology commercialization veteran Ameet Mallik was appointed to the Board of Directors. Ameet brings to Atara's Board a wealth of experience with US payers, access and reimbursement strategies and launches of innovative oncology therapy, including CAR Ts. Now turning to Europe, where we're also making excellent progress. We recently had successful pre-submission as well as Co-Rapporteur and Rapporteur meeting with the EMA, and cleared all compliance checks, so we can now move forward to submit the EU market authorization application for patients with EBV positive PTLD in November of 2021. In parallel, there is a strong level of interest from ex-US partners and our partnering discussions are progressing very well, in line with our expectation to secure a partner for Europe by Q4 2020. Meanwhile, we are also actively enrolling patients in our tab-cel Phase 2 multi-cohort study in other EBV-driven cancers. The six study populations of which the largest through our EBV positive AID LPD, and EBV positive PID LPD may support meaningful labor expansion beyond second-line PTLD. Turning now to ATA188, our transformative product candidate for patients with multiple sclerosis. I'm very excited to announce that important new data will be presented in October ECTRIMS. This would include new magnetization transfer ratio imaging data and imaging biomarker linked with myelination in addition to the two-year clinical data update from the Phase 1a open-label extension study. We are excited to present this new data, and Jakob will have more to say in a moment. Meanwhile, we continue to make progress in enrolling the Phase 2 randomized double-blind placebo-controlled study or EMBOLD study. We are on track to conduct an interim analysis of the study in the first half of 2022, including efficacy and safety in patients with progressive forms of MS. Following this interim analysis, we expect to have further discussion with the FDA regarding potential study adjustment for pivotal intent. These are important discussions from both a regulatory and strategic perspective for the program and could provide optionality on how we advance development. Momentum meanwhile continues to build in the community reinforcing the association between EBV Epstein-Barr virus and MS, and the transformative potential of ATA188 for MS patients. This was confirmed by a recent survey amongst top US neurologists. We also continue to see significant interest from a number of large companies regarding a potential collaboration involving ATA188. As we truly have a unique asset, the only investigational therapy in a randomized controlled trial in progressive MS with disability improvement as the primary end point. Moving to our CAR T portfolio and first, our mesothelin franchised program ATA2271 and ATA3271. These mesothelin targeted CAR T products are benefiting from a global strategic collaboration with Bayer, which is off to a strong start. For ATA2271 or autologous mesothelin CAR T program, we expect to present the first update on Phase 1 data for patients with advanced mesothelioma in Q4 2021. The off the shelf allogeneic version of this mesothelin CAR T program, ATA3271 using a PD1 dominant-negative receptor and 1XX CAR cosignatory signaling domain built on our EBV T-cell platform is currently in IND enabling studies and is progressing well. We expect Bayer to submit an IND in the second half of 2022 and subsequently lead clinical development and commercialization activities. Turning to ATA3219 or allogeneic CD19 targeted CAR T for patients with decent malignancies. We've got to submit an IND in Q1 2022, in line with our strategic goal to develop this asset as a best-in-class for B-cell malignancies. Moving to our financials, with regard to our cash positions and runway, our cash burn in Q2 was $61.8 million, and we ended the second quarter of 2021 with $373.4 million in cash. With this cash balance and our updated and well-controlled plan expand profile, we believe we are sufficiently funded into 2023. As we turn ahead into the third quarter of 2021, I am delighted to see how far Atara has come from this time a year ago. Each and every one of our staff has delivered on our goal of saving and improving lives of patients with serious disease. On a daily basis, we partnered closely with clinical study site, with our manufacturing and logistic partners and our collaborators in order to ensure patients would continue to access cell therapies. With the hard work of the Atara team, we are on a clear path to file top cell regulatory submissions and bring this life-saving medicine to patients in need. I will now turn the call over to Jakob. Jakob?
Jakob Dupont: Thank you, Pascal. I am pleased to provide further details on the progress we made during the second quarter in advancing our three strategic priorities. Starting with tab-cel, we have aligned with the FDA on several key aspects required for BLA submission. Regarding comparability of tab-cel clinical and commercial product, we reached alignment on methodologies for evaluating these two sets of products. As requested by FDA, we are providing data on nearly all pivotal and commercial tab-cel lots manufactured to date. We believe FDA should agree on our comparability data package when we discuss these new data at an upcoming Type B CMC meeting. This belief is directly related to the consistent and tightened process performance data that was generated from the pivotal and commercial production campaigns, as well as the fact the process changes between pivotal and commercial were minimal and mainly related to the commercial GMP compliance of the EBV viral reagent used in manufacturing. With regard to comparability of historical non-pivotal tab-cel product versus pivotal clinical study product, the agency recently clarified that they would like to see comprehensive analytical data on most historical lots. Therefore we have agreed with the FDA that comparability cannot be established because we do not have product available for some of the lots manufactured by MSK in the past. This important resolution of comparability means that clinical data generated using historical non-pivotal product will not be pooled with pivotal clinical data. Importantly, this decision is consistent with the prior FDA decision to evaluate in parallel the data of a CAR T product from an academic center's non-pivotal product versus the industry partner's pivotal clinical study product for which ultimately, the FDA granted marketing approval. Turning to the pivotal ALLELE study. We have recently successfully completed the analysis of the Q2 data cut requested by the FDA for the Phase 3 ALLELE pivotal study. Top line data evaluated through independent oncologic and radiographic assessment shows strong ORR in line with prior results with half the patients responding and a safety profile consistent with previously published data with no new safety signals. Importantly, this new data cut demonstrates new robust durability of response. This latest data cut is what we plan to use as the basis for both the BLA and the MAA submissions while also providing additional supportive data from our historical non-pivotal studies expanded access and compassionate use study patients. To summarize the next steps, we anticipate speaking with the FDA in a Type B CMC meeting to discuss our expanded data package on comparability between pivotal clinical study product and commercial product, as well as a Type B clinical meeting to discuss the latest data cut from the ALLELE study now with robust durability of response data requested by the agency that will form the basis of the BLA filing. Request to FDA for these meetings have already been made and pending alignment we could then file the BLA in the first quarter of 2022. As Pascal mentioned, we've also made excellent progress in Europe. Tab-cel's prime and orphan drug designation with EMA has enabled regular engagements with the agency and our PIP compliance checks have been successfully cleared. Our recent successful pre-submission, as well as Co-Rapporteur and Rapporteur meetings, means that we have cleared the path for the MAA submission in the EU. Therefore, we can submit the market authorization application for patients with EBV positive PTLD in November of 2021. Taking a step back and thinking about PTLD patients in dire need of treatment options, we recently joined the rare disease company coalition alongside other rare disease leaders and constituents to engage in conversation with policymakers on the need for speed and access for life-changing therapies. Atara is committed to leading the path forward for transformational therapies for rare disease patients. Moving now to ATA188, our product candidate for progressive multiple sclerosis. We are excited and look forward to presenting at ECTRIMS in October, long-term, two-year clinical data from the Phase 1 open-label extension, and new translational data from the Phase 1 study of ATA188 in progressive MS. Included will be new imaging biomarker data considered to reflect the state of myelination in the CNS known as magnetization transfer ratio or MTR. With respect to MTR, decreased MTR in MS lesions may correlate with demyelination and axonal loss in MS patients, while increased MTR may correlate with remyelination. These data may provide key information on the mechanism of EDSS improvement in our ATA188 clinical data. We are excited to present these new data in October. We also plan to use MTR as a relevant imaging biomarker correlated with disability improvement in our ongoing Phase 2 EMBOLD study. Turning now to our CAR T programs. In addition to Pascal's comments, I would also add that we are making excellent progress on our mesothelin franchised programs with our partner Bayer. This partnership is helping to demonstrate the progress of the technical and manufacturing elements of our EBV T-cell platform. We are delighted to leverage the capabilities of such an experienced company as Bayer and look forward to providing further updates later this year. ATA3219, our allogeneic CAR T for patients with B-cell malignancies is also advancing well and we believe that this therapy could be a best-in-class treatment in B-cell malignancies as there is still a significant unmet need despite increased therapeutic options. Finally, I would like to extend a warm welcome to our newest leadership team member, Chief Scientific Officer, Dr. Cokey Nguyen. Cokey comes to us most frequently or most recently from Fate, and brings his deep experience in CAR T paired together with a strong conviction around the unique benefits of our EBV platform to drive our exciting CAR T cell franchise forward into the future. I'll now turn the call back to the operator to begin the Q&A portion of the call. Operator?
Operator: At this time, we'll be conducting a question-and-answer session. Our first question comes from the line of John Newman with Canaccord Genuity. You may proceed with your question.
John Newman: Hi, there. Thanks for taking my question and congrats on the good progress here. Jakob, you mentioned the submission has been made, a request for a Type B meeting with the comparability data for tab-cel. Just curious if you know about when that might take place? And then on the clinical side, beyond the most recent data look for ALLELE that you've conducted, just curious if you think the agency will require any additional data looks in the future, maybe either with some additional patients for a longer follow-up? Thanks.
Pascal Touchon: Thank you, John, for your question. Jacob, do you want to take the first one?
Jakob Dupont: Yes. Thanks, Pascal, and thank you, John. So yes, we have submitted a meeting request for the Type B meetings both for CMC comparability and for the clinical discussion as well. Now, per PDUFA timelines, we should hear back from the agency within 60 days of that request, so we believe that this meeting will occur within the next two months.
Pascal Touchon: And the second question on clinical data beyond ALLELE.
Jakob Dupont: Yes, absolutely. So we believe that this new analysis for ALLELE is strong enough to support a BLA filing. But of course, if the FDA wants updates specifically such as safety with a subsequent 90 days safety cut, we can certainly do that. But we do believe that the current Q2 data cut for ALLELE is sufficient to support the BLA submission, as well as the MAA application. And as you know, we're also going to be providing historical non-pivotal data and EIP and SPU clinical data in the BLA and MAA filings in parallel, but not in a pooled fashion due to the outcome, which we thought was quite favorable in terms of non-comparability between historical and pivotal material.
Pascal Touchon: Does it answer your question, John?
John Newman: Yes, it does. Thank you.
Pascal Touchon: Thank you.
Operator: Our next question comes from the line of Jonathan Miller with Evercore ISI. You may proceed with your questions.
Jonathan Miller: Hey, guys, thanks for taking my questions, and congrats on the progress. It does seem like the FDA is being pretty cautious on the tab-cel BLA. I guess given that you can't pool and that you think the Q2 update on ALLELE is as far as you're going to need to go, what is the duration of response that you'll be able to claim on the pivotal data relative to what you could have claimed on the pooled data? Separately, it seems like IND timelines for the allogeneic CAR T programs are going to be a little bit back towards the back end of the prior guidance. I just wondered, what's the gating factor on those INDs going forward from here?
Pascal Touchon: Thank you for your question. Do you want to take the first question, Jakob, please?
Jakob Dupont: Yes, absolutely. So I would say that we've made great progress with the FDA in terms of understanding the comparability issues and then obviously, also providing this Q2 data cut that the FDA requested from us in October of last year, specifically to provide durability data on the patients that had already enrolled. Now, the guidance that the FDA has provided to us which they provide to other sponsors is that they want to see durability of that response which basically means that from the time that a response is detected, you want an additional six months of follow up on those patients since the time of response. So, if you think about we got that guidance in October of last year, we let the data mature further, collected the data based on a Q2 data cut and provided it to our independent review facility for independent oncologic and radiographic response. It really fits those criteria of six months duration of response after that initial response is detected. And that's a pretty standard request from the agency.
Pascal Touchon: Yes. Another thing the fact that we align with the agency on the durability of response they want to see, and we have this data now makes us very confident in the strength of this data package that we will present in forthcoming Type B clinical meeting. So on your second question, is just that we have refined our thinking on the different manufacturing timelines for this program and development that is needed to file the IND, the work we are doing on this platform as we progress on the specific programs we by the way, help the rest of the early pipeline and we are leveraging our platform there. So there is no particular aspect there that is a particular challenge apart from the fact that we have now fine-tuned the exact timing for the IND filing and for ATA3219 will be of course, Atara filing the IND, versus for ATA3271 will be Bayer filing the IND there. Now, we also trying in developing this IND package, make sure that we can optimize our chance of adding two best-in-class platforms for allogenic CAR T, and this is we believe where ATA3219, in particular, could have a significant potential advantage in optimizing characteristic of the cells to make sure that we can leverage the innate properties of EBV T-cells together with 1XX as a costimulatory domain to really make something that could go to the clinic with the potential and the goal to be a best-in-class in B-cell malignancies. Does it answer your question, Jon?
Jonathan Miller: Yes, absolutely. Thank you.
Operator: Our next question comes from the line of Salim Syed with Mizuho Securities. You may proceed with your question.
Salim Syed: Great. Good afternoon, guys, and congrats on the progress. A couple from me if I can on ATA188. So, Pascal, you sound pretty excited, and I know the press release even uses that word exciting, new imaging data. So as much as you can say here about the MTR and whether that actually refers to myelination patterns, are you seeing or you think you're seeing remyelination with ATA188? And curious to get your thoughts on the FDA being able to use this as a biomarker for accelerated approval just given everything we've seen with accelerated approval around Alzheimer's. Thank you.
Pascal Touchon: Thank you, Salim. We are definitely excited but we are not going to give you the data that you will have to wait for October. But AJ, do you want to comment on MTR and what we believe this particular set of data is very important? And what's your plan with the FDA in terms of how this could be used as a biomarker?
AJ Joshi: Yes. Thanks, Pascal. Hey, Salim. Yes, I think with the MTR data, you've heard that it's pretty much the -- when you look at MRI biomarkers, looking at myelination that's really the most used one in all the studies that you're looking at. And as you might imagine, it's been correlated with a decline in EDSS so a decline in disability. So if you have lower MTR, you actually have -- lower MTR means you have demyelination and that means you have a decline in disability. So that correlation has been made, what's interesting is no one has actually shown improvement because as you know no product has shown improvement in disability in the progressive situation. But what is interesting is if you take a look at MTR in relapsing disease, so this is where you've got an active lesion and you use a therapy that works in inflammatory disease, you will actually see MTR increase because you get remyelination once the inflammation comes down. So you do see MTR increasing when you have remyelination, it should never been shown in the progressive setting. So from that standpoint, what we're trying to do is we're trying to say look, MTR is relatively established as a measure of myelination both demyelination and re , and we're now trying to apply that to the study data that we have now. So obviously, we're looking forward to presenting the data coming in October. And in terms of how you could leverage this going forward, it's really not been used as anything like a surrogate marker or anything like that to date. But again, a lot of that we think is just because there hasn't been a lot of good reason to take a look at disability improvement and MTR changes. So certainly, we're going to very closely monitor MTR throughout the course of the EMBOLD study, and we're going to be talking to FDA and we will be, including all of the MTR discussions in those conversations. But today, it's a little bit too early to say, yes, this is going to be an established biomarker. But from a scientific perspective and the clinical perspective it is established within the scientific community right now.
Pascal Touchon: Yes. And as AJ has said, it will be -- one of the endpoint will be following in the current randomized control trial. So not only we have data coming in October on the Phase 1, but we will have also data coming forward later on the Phase 2 study when we get access to this data. So that's something of a plan in terms of leveraging this particular biomarker that has been used in a number of studies, but not yet correlated with improvement in disability, and that could be something very exciting.
Salim Syed: Super helpful. Thanks so much.
Operator: Our next question comes from the line of Phil Nadeau with Cowen. You may proceed with your question.
Phil Nadeau: Good afternoon, and congrats on the progress, and thanks for taking our question. A couple on the comparability issue. You mentioned briefly in the prepared remarks, what the differences are between the pivotal and commercial material. Could you go into a bit more detail at the significance of those differences? And then in a secondarily, now that the methodologies have been clearly defined, you talk a bit more about your confidence that the FDA will find the pivotal and commercial material comparable. Thanks.
Pascal Touchon: Certainly, Jose, do you want to address the first question on the difference between pivotal and commercial material? And then Jakob, you can address the second question on the FDA, how we perceive the confidence that we have data that will be seeing them to decide positively on comparability. Jose?
Jose Vidal: Certainly, Pascal. Yes, the difference is the actual source and grade of the Epstein-Barr virus that we use in the manufacturing process, we switch from a clinical research grade producer cell line to producer virus into a full GMP commercial-grade producer cell line, and we switch also the manufacturing place of the virus to our own facility from the previous CMO as the CMO has no capacity to supply commercial volumes. We have done full characterization on that and we are pretty confident that it's a minimal change, but that's the summary of the change between the pivotal and clinical material.
Pascal Touchon: Thank you. And Jakob on how do we see the data package for the FDA?
Jakob Dupont: Absolutely. So I think one of the really important things so that we learned from the FDA is their thinking evolved around tab-cel which is the -- as you know, the first allogeneic T-cell product which is going across for FDA approval. We learn that they have this requirement now to see the data from all the lots that have been created in order for determination of comparability to be made between pivotal material and commercial material. That was the reason why we could not deem comparability between historical and pivotal because we simply didn't have some of the lots from Memorial Sloan Kettering. But what we do have are virtually all of the lots from pivotal and commercial so that we can do full comparability analysis. So having the agency, give us the lay of the land and what the requirements were in terms of sharing the totality of that data, that is something that's -- that is really accomplishable from our perspective. And having that clarity from the agency is really valuable, so that's why we put the Type B meeting request in which again will occur within the next 60 days or so, and we will put to them exactly that question of, have we now secured this comparability with the full data package with the help of Jose and his full team in CMC manufacturing. And we believe that we're going to achieve this because we know what the rules of engagement are.
Pascal Touchon: Yes. And we're pretty much sure that the data set we have is really very robust due to the robustness of our manufacturing process performance and the minimal changes that we've made between pivotal and commercial process, as Jose just explained. Does it answer your question?
Phil Nadeau: Great. And it is my last question. Yes. Maybe one I just want to ask, what's the rate-limiting factor to the Q1 filing? Is that comparing -- is that completing the comparability analysis, or is there something else that's getting?
Pascal Touchon: Jakob?
Jakob Dupont: Yes. So to provide these details, so as mentioned, we want to have the Type B CMC meeting within 60 days to solidify the issue of comparability of pivotal to historical, so that we'll get taken care of. Then we have the Type B meeting for clinical where we share the most recent data cut from ALLELE and we get the agency agreement on that. Now that hopefully is going to solve most of the issues. Now, there may be some more administrative issues that could get taken care of in a pre-BLA meeting, so our base case is, have these two type B meetings with the FDA and then after that have a pre-BLA meeting that leads to a Q1 completion of the BLA filing. Now, there is an outside chance that if we secure all the issues in these two type B meetings that we may be able to have a faster submission of the BLA. But frankly, our base case is to say, we need to have these two type B meetings then the pre-BLA meeting and then we complete the submission of the BLA.
Phil Nadeau: Perfect.
Pascal Touchon: And what makes us confident there is again the strength of the data. We know the data in terms of clinical data there from the ALLELE data cut in Q2 and very strong. We know the robustness of our process and we have all the data needed to provide the FDA with substantially all the lots of the data and all the lots made by Atara. So in terms of delivering what the FDA is asking for, we feel very clear.
Phil Nadeau: That's very helpful. Thanks for taking our questions.
Operator: Our next question comes from the line of Matt Phipps with William Blair. You may proceed with your question.
Matt Phipps: Good afternoon, and thanks for taking my question. There are few. First, was it always the plan to have a Type B clinical meeting after the Q2 data cut? It just seems like that would kind of made it impossible to previously have hit your guidance for Q3 submission -- completing that submission regardless of obviously the CMC issues. So just wondering if that is something new because again doesn't seem like that lines up with your previous guidance on timelines outside of obviously the CMC issues.
Pascal Touchon: Okay. So let me answer the first question on the guidance, and then you say that you have some other questions. Now, I think when we put the guidance on Q3, it was really based on the Type B CMC meeting that we had in Q2. And on the basis that following that Type B CMC meeting, we could then move from a pre-BLA meeting and -- in the August timeframe based on the data cut and then go with that with the submission of the BLA by the end of the Q3. That was basically the guidance basis there. Now what's happening is we have the two aspects. Now, we have the new data on the ALLELE data set and then we have at the same time the data coming from this request of the FDA that we'll have the need to see all the manufactured or nearly all the manufactured lot by Atara there. So we aligned with the FDA during our recent interactions and that was just a couple of weeks ago where that's the best way forward will be to ask in parallel a Type B meeting on the CMC aspect, so that meeting on clinical so you can look at the clinical data out there and then we can have a pre-BLA that will just be the more check the box administrative part of the pre-BLA meeting. So that's why it's put together with this two Type B meeting and then a pre-BLA, and in the past, it was supposed to be to move directly from the Type B CMC to a pre-BLA. Jakob, anything to add to that?
Jakob Dupont: No. I think that you've summed it up very well, Pascal.
Pascal Touchon: Does it answer your question, Matt?
Matt Phipps: Yes, I guess. It seems like maybe there is something's that come up that's required another Type B meeting since that obviously wasn't planned originally, but okay. Just wondering you've previously said that you had about 15 lots manufacturers from comparability. I wonder if that's still kind of the number you plan to go into this Type B meeting with on the CMC side. Or if there is any additional lots that will be used in the comparability?
Pascal Touchon: Yes. Maybe Jakob, do you want to start and Jose can chime in if needed.
Jakob Dupont: Yes, absolutely. So, Matt, I think this really speaks to how the thinking of the FDA has evolved and where we now have this clarity of guidance because you're right, what we presented to the agency was 15 lots from each process version, which really gives us robust statistical power for that comparison. Now, for example, if you talk about a small molecule inhibitor or you talk about an antibody, generally speaking, they want about three lots to compare statistics on that. We're providing 15 of each process version, but then the agency came out and said, listen, we really want to assess all your lots for pivotal and commercial, which is really more consistent with the request that they made for ALLELE CAR T because --
Jose Vidal: Autologous.
Jakob Dupont: I'm sorry, auto CAR T. I'm sorry, Auto is what I am referring to where each one of those products -- each one of those cell products was an individual drug for that individual patient, so the agency wanted to see every single one of those. Now, the whole idea with allogeneic T cell therapy is that you're able to treat many patients from your inventory, so you don't need to make one product from each patient. So we have proposed this robust statistical approach where we gave them 15 lots from each of the process versions and -- but the agency did fall back to this approach with us and said we want to see all lots and we said, okay, fine, we can deliver that with our pivotal to commercial material. And that's exactly what we're providing to them in this Type B CMC meeting which is where we have confidence that we're going to be able to resolve this comparability issue.
Pascal Touchon: Jose, anything do you want to add?
Jose Vidal: Yes. To the question of beyond the 15 lots for process variation, in total, we're representing now 74 lots to the agency.
Matt Phipps: Okay. All right.
Pascal Touchon: Yes. And that represents more than 95% of the total lots produced, so that's exactly what the agency wants to see. And we believe that the main rationale is that they want to confirm the robustness of the manufacturing process for cell therapy and are they used to with autologous, you know, they have habits now.
Matt Phipps: Okay. One last question on the magnetic transmission, the MTR data that we're going to see is just like you've collected on every patient? Or how many patients should we expect as I can't recall this being something that was listed as a data being collected? And just -- will it be -- how many times does it a pre-treatment and then now 12 or 18-month follow-up, what kind of -- can you give us anything else on what to expect here?
Pascal Touchon: AJ?
AJ Joshi: Sure. So the way the MTR works is it's really analysis, you can do when you've got a good quality MRI done. So when you have a good quality MRI result, you can actually go ahead and do the interim analysis at whatever time points. So for-- as you know for our Phase 1 study, we did six months and 12 months' time points for EDSS, so that's the kind of thing we'll be looking to talk about in the -- with MTR. And then going forward in the RCT, literally every single time point that an MRI is done, we'll be able to assess the MTR as well.
Pascal Touchon: And on the number of patients, that's all the patients in a Phase 1.
AJ Joshi: All the patients that have a good MRI will have results there, yes.
Matt Phipps: Okay, great.
AJ Joshi: In the Phase 1, yes.
Pascal Touchon: Yes.
Matt Phipps: Yes.
Operator: Our last question comes from the line of Ben Burnett with Stifel. You may proceed with your question.
Unidentified Analyst: Hi, this is Kylie Brisa on for Ben Burnett. Thanks for taking our questions. We just have two kind of quick ones. I was wondering if you guys could give any additional color on what we might see at the ATA2271 read out the first one in terms of maybe duration of response or the number of patients we might see? And then additionally, I'm wondering -- I had a question for ATA3219, if you guys are planning on releasing any preclinical data for that? Thank you.
Pascal Touchon: Thank you for your question. Jakob, do you want to take these questions?
Jakob Dupont: Yes, absolutely. So thank you for the question. In terms of ATA2271, which is our autologous mesothelin CAR T program, which we're doing with Memorial Sloan Kettering, obviously, it's in the Bayer partnership as well. As we've announced, we do plan on presenting the first clinical data at a relevant meeting medical meeting before the end of this year, so we are certainly intending on presenting that clinical data. Now, we do plan on presenting safety, efficacy biomarker data from this study, and we have enrolled the first cohort of patients on the study with our partners at MSK, and we are currently enrolling the second cohort as well. So again depending on data maturity and so forth, you'll see these various elements. And I do want to highlight this program, we think it's really quite innovative and interesting because, yes, it's autologous and it has this 1XX costimulatory domain that we've been licensed from Michel Sadelain and his team, which we think is a potentially best in class costimulatory domain for CAR T, and it also has the PD1 dominant-negative receptor, which provides intrinsic overcoming of the immunosuppression of tumor PD-L1, so the auto program has both of these components. Now, obviously, we're working also on the allogeneic program ATA3271 and that's moving towards an IND filing, where at this point, we're leveraging our EBV T-cell platform additionally there. Now in terms of ATA3219, and we're very excited about that program. It's our first allogeneic CAR T-cell program out of the gate. It's directed again CD19. We do believe this is a best-in-class potential program. And we did present at ASH last year, in 2020, a preclinical data from that ATA3219 program, so we can certainly -- that data is certainly available from ASH, and that also leverages this 1XX costimulatory domain from Dr. Sadelain and his team at MSK, and we're excited about that forthcoming IND submission. Pascal anything further?
Unidentified Analyst: Great.
Pascal Touchon: No. The only thing is to remind everyone that this program is also we believe supported by this clinical proof of principle that was established by the team at Memorial that's true at the Congress in 2020 that similar type of construct based on EBV T-cell from healthy donors to which they have added CD19 CAR T, in that case, with the traditional costimulatory domain, then they treated patients with advanced B-cell malignancies and they achieved an 83% CR rate. And that study was quite amazing and unique in a sense that they followed patients for a very long time and that CR rate was maintained over a median follow-up of nearly two years. So I think that's really a very impressive data set albeit on the small number of patients, but with long durability of response and excellent safety. So that's a nice proof of principle for what we want to achieve there as a potential best-in-class, in particular, adding now 1XX as a costimulatory domain. Any further questions?
Unidentified Analyst: That's it from me. Thank you.
Pascal Touchon: You're most welcome.
Operator: That concludes our question-and-answer session for today. Thank you for joining the Atara Biotherapeutics second quarter 2021 financial results conference call. You may disconnect your lines at this time.
